VXRT LONG term investment
Vaxart (NASDAQ:VXRT) The company is working on a vaccine for the novel coronavirus that works via tablets instead of injection. If Vaxart reports positive results from this clinical trial, investors will likely see shares of VXRT stock soar higher. Be first to capitalize on, in my opinion the best alternative for Covid 19, a oral pill solution
Good luck
Good luck
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.